FDA Approves Drugs for Cervical, Breast Cancer - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     FDA Approves Drugs for Advanced Cervical Cancer, Most Common Type of Breast Cancer 10/27/2021 Two previously published NCI Cancer Currents blog posts have been updated with new information about recent drug approvals by the Food and Drug Administration (FDA). New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma, originally published August 2, 2018, now includes an update about FDA's approval of pembrolizumab as part of a combination therapy and as a single agent for people with advanced cervical cancer.   An update has also been added to Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer with information about FDA's approval of abemaciclib for some people with HR-positive, HER2-negative breast cancer following surgery. The original post was published January 26, 2021.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892